Navigation Links
Tumors Targeted Naturally

Scientists from University of Wisconsin-Madison claim that they can efficiently seek out and kill cancer cells while leaving out healthy cells//. This is very similar to the Nature's way of distinguishing one type of cell from another.

The new tumor targeting strategy, presented today (March 25) at the annual national meeting of the American Chemical Society, cleverly harnesses one of the body's natural antibodies and immune responses. "The killing agent we chose is already in us," says UW-Madison chemistry professor Laura Kiessling, who led the work with postdoctoral researcher Coby Carlson. "It's just not usually directed toward tumor cells."

In a series of cell-based experiments, the researchers' system recognized and killed only those cells displaying high levels of receptors known as integrins. These molecules, which tend to bedeck the surfaces of cancer cells and tumor vasculature in large numbers, have become important targets in cancer research.

In contrast, an established tumor-homing agent linked to the cell toxin doxorubicin destroyed cells even when they expressed very little integrin, indicating this strategy has the potential to kill cancerous and healthy cells indiscriminately.

"This study suggests that the cell recognition mode we used can direct an endogenous immune response to destroy cancer cells selectively," says Kiessling. "We think this could lead to a new class of therapeutic agents not only for cancer but also for other diseases involving harmful cells."

Cancer cells typically display higher levels of certain receptors on their surfaces than do normal cells, a fact that allows scientists to pinpoint tumor cells lurking among the body's scores of cell types. A popular approach employs a cell-binding agent, such as a monoclonal antibody, that is powerfully attracted to the target receptor and holds fast to any cell displaying it.

Although this strategy has benefits, it's not natural, says Kiessling. Cell recognition in living systems instead involves binding agents that attach only weakly to any single target receptor, and thus stick to cells only when several receptors are displayed together. These weak "multivalent" interactions cut down on cases of mistaken identity, because if the agent contacts the wrong cell type, it can be easily displaced.

The team got the idea to mimic this process from efforts to transplant pig organs into primates. The surfaces of most mammalian and bacterial cells express large amounts of a carbohydrate, called alpha-Gal in scientific shorthand, while the cells of humans and other higher primates do not. What humans and primates do produce in abundance is an antibody against the carbohydrate, called anti-Gal.

When scientists tried transplanting pig organs into primates, the anti-Gal antibodies bound to the alpha-Gal on the organ's cells, unleashing a potent immune response that caused immediate organ rejection. But true to natural cell recognition, the immune response occurs only when clusters of many alpha-Gal molecules are present for anti-Gal to bind with.

Armed with this knowledge, Kiessling's group modified an agent known to bind tightly to integrin and tethered it to alpha-Gal. When they mixed this molecule with cells displaying high levels of integrin, the agent, by attaching to the receptor, decorated the cells with large amounts of alpha-Gal. In cell cultures containing human serum, the alpha-Gal then elicited the cell-destroying immune reaction.

In cells with low concentrations of integrin, the agent still bound, but the resulting levels of alpha-Gal weren't sufficient to elicit the immune response, and the cells survived. The same wasn't true if the cell-binding agent delivered doxorubicin to cells instead: They were killed regardless of the amount of integrin they carried.

Because target receptors on cancer cells usually reside on healthy cells, too - albe it in lower numbers - therapies aimed at these receptors are always expected to have debilitating side effects. That's why Kiessling's approach holds such promise.

"What we've shown is that you don't need a receptor that's found solely on tumor cells," she says. "You just need one that's found in significantly higher numbers on cancerous cells than on normal ones."

Source-Eurekalert
JYT
'"/>




Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Radiofrequency Energy Cooks Tumors Without Surgery
3. New Technique For Benign Breast Tumors
4. Another Treatment Option for Benign Tumors
5. Understanding The Origin Of Tumors
6. Outpatient Treatment Possible For Patients with Uterine Fibroid Tumors
7. Mutated Viruses Can Cure Tumors
8. Exposure to Grating, Noise, Music Can Cause Tumors Leading To Deafness
9. Use Of Mobiles Does Not Result In Tumors
10. Treatment Resistant Tumors Can Be Targeted Better Using Botox
11. Link Between Cell Phones Use and Brain Tumors Established
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2017)... ... ... Braun Industries will be participating as an exhibitor at EMS Today 2017. ... 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake ... on display. , “JEMS is a leader in EMS news and education. ...
(Date:2/19/2017)... ... February 19, 2017 , ... "At your fingertips" electronic ... MEDfx and the Delaware Health Information Network (DHIN) have partnered to improve connectivity ... state-wide health information exchange, DHIN stores and shares real-time health data for more ...
(Date:2/18/2017)... (PRWEB) , ... February 17, ... ... Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, ... Are manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced ...
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/18/2017)... ... 2017 , ... Park Cities Pet Sitter President, Joette White, has been featured ... network. The episode, which was posted this week, features a 30-minute interview of ... Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Pa. , Feb. 16, 2017 Absorption ... biologics, and medical devices, is pleased to announce that ... has been selected as a winner of the 2017 ... SmartCEO Magazine and recognizes driven executives for their ... work ethic. The awards ceremony and celebration is on ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
(Date:2/16/2017)... YORK , Feb. 16, 2017 Summary ... agreements entered into by the worlds leading healthcare companies. ... Description The Global Allergy ... to partnering deals and agreements entered into by the world,s leading ... - Top deals by value - Deals listed by company ...
Breaking Medicine Technology: